Differentiation, Transcriptomic Profiling, and Calcium Imaging of Human Hypothalamic Neurons

Autor: Chen, Hsiao-Jou Cortina, Mazzaferro, Simone, Tian, Tian, Mali, Iman, Merkle, Florian T

Neurons in the hypothalamus orchestrate homeostatic physiological processes and behaviors essential for life. Human pluripotent stem cells (hPSCs) can be differentiated into many types of hypothalamic neurons, progenitors, and glia. This updated unit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6a2703f92e4fcb627052c528addd97d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Autor: Bashi AC; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Coker EA; Wellcome Sanger Institute, Cambridge, United Kingdom., Bulusu KC; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jaaks P; Wellcome Sanger Institute, Cambridge, United Kingdom., Crafter C; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lightfoot H; Wellcome Sanger Institute, Cambridge, United Kingdom., Milo M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McCarten K; Wellcome Sanger Institute, Cambridge, United Kingdom., Jenkins DF; Oncology R&D, AstraZeneca, Waltham, Massachusetts., van der Meer D; Wellcome Sanger Institute, Cambridge, United Kingdom., Lynch JT; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Barthorpe S; Wellcome Sanger Institute, Cambridge, United Kingdom., Andersen CL; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barry ST; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Beck A; Wellcome Sanger Institute, Cambridge, United Kingdom., Cidado J; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Gordon JA; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hall C; Wellcome Sanger Institute, Cambridge, United Kingdom., Hall J; Wellcome Sanger Institute, Cambridge, United Kingdom., Mali I; Wellcome Sanger Institute, Cambridge, United Kingdom., Mironenko T; Wellcome Sanger Institute, Cambridge, United Kingdom., Mongeon K; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Morris J; Wellcome Sanger Institute, Cambridge, United Kingdom., Richardson L; Wellcome Sanger Institute, Cambridge, United Kingdom., Smith PD; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Tavana O; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tolley C; Wellcome Sanger Institute, Cambridge, United Kingdom., Thomas F; Wellcome Sanger Institute, Cambridge, United Kingdom., Willis BS; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Yang W; Wellcome Sanger Institute, Cambridge, United Kingdom., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McDermott U; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Critchlow SE; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Mettetal JT; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Garnett MJ; Wellcome Sanger Institute, Cambridge, United Kingdom.

Publikováno v: Cancer discovery [Cancer Discov] 2024 May 01; Vol. 14 (5), pp. 846-865.